← board
GRCE
distress 2/10 · well-funded / low risk$2.35-1%today-54% from 52w high
Lead: aneurysmal subarachnoid hemorrhage
Revenue
pre-revenue
Liquidity
$17M
Runway
1.1 yrs
Shares 1y
+18%
Price & events
-38.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.8%
1D
-2.5%
1W
-1.7%
1M
+0.0%
3M
-38.5%
6M
-29.9%
1Y
-18.4%
2Y
-89.8%
5Y
-87.8%
All
Overview
- Market Cap
- $38.24M
- Volume
- 2.89K
- 52 Week Range
- $2.10 – $5.13
- Total Shares
- 16.27M
- Float Shares
- 13.59M
- Short %
- 12.23%
- % Held by Insiders
- 25.73%
- % Held by Institutions
- 26.46%
- RVOL
- 0.01x
- Beta
- 0.37
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 9
- 2026-04-23crlGTx-104 · FDA issued Complete Response Letter for GTx-104 NDA for aSAH citing CMC and non-clinical issuesSEC 8-K
- April 23, 2026PDUFAPDUFAGTx-104 · PDUFA target date for NDA reviewSEC 8-K
- September 2025conferencedata presentationsecondaryPhase 3GTx-104 · Phase 3 STRIVE-ON trial data presented at Neurocritical Care annual meetingSEC 8-K
- 2025-08-22fda agreementGTx-104 · FDA accepted NDA for formal reviewSEC 8-K
- 2025-08-22filing acceptanceFiled (NDA/BLA)GTx-104 · FDA accepted NDA for formal reviewSEC 8-K
- First Half of 2025regulatory submissionFiled (NDA/BLA)GTx-104 · NDA submission for GTx-104 expected in H1 2025SEC 8-K
- 2025-04-09fda agreementGTx-104 · FDA alignment on NDA submission requirementsSEC 8-K
- early calendar 2025readoutPhase 3GTX-104 · Data readout from STRIVE-ON safety trialSEC 8-K
- November 20, 2024conferencedata presentationsecondaryGTx-104 · Virtual KOL event on GTx-104 in aSAHSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $6 (+153% upside) · 2 analysts
- 2026-04-24TD CowenBuy
- 2025-02-18HC Wainwright & Co.Buy
Competitors — aneurysmal subarachnoid hemorrhage
- none identified
Recent news
- 2026-07-15Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therape - The National Law Review
- 2026-07-05Grace Therapeutics Q2 2026 Earnings: Narrower Net Loss Beats Consensus - Earnings Power Value - dars.gov.et
- 2026-07-04Grace Therapeutics (GRCE) price target decreased by 47.83% to 6.12 - MSN
- 2026-07-03GRACE THERAPEUTICS INC (GRCE) Stock Chart - ChartMill
- 2026-06-25GRCE Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-22Grace Therapeutics (NASDAQ: GRCE) Reports FDA CRL, Schedules Meeting - Value The Markets
- 2026-06-18Grace Therapeutics sets FDA meeting after GTx-104 CRL - Stock Titan
- 2026-06-18Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update - The Globe and Mail
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.